A-METHAPRED
Clinical safety rating: caution
A-METHAPRED (methylprednisolone) is a synthetic glucocorticoid used for its potent anti-inflammatory and immunosuppressive properties. It is indicated for a wide range of conditions including autoimmune disorders, allergic reactions, and respiratory diseases.
Methylprednisolone is a synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators such as cytokines, prostaglandins, and leukotrienes. It also induces lipocortin synthesis, inhibits phospholipase A2, and reduces immune cell activity.
| Metabolism | Primarily hepatic via CYP3A4 enzyme system, with minor contributions from other pathways. |
| Excretion | Renal (mainly as inactive metabolites); <5% unchanged. Biliary/fecal excretion is minimal. |
| Half-life | 2-3 hours (terminal); clinical effect persists longer due to intracellular receptor binding. |
| Protein binding | 74-90% bound primarily to corticosteroid-binding globulin (CBG) and albumin. |
| Volume of Distribution | 1.0-1.5 L/kg; indicates extensive tissue distribution. |
| Bioavailability | Oral: ~80%; IM: ~100%. |
| Onset of Action | IV: immediate (minutes); IM: 1-2 hours; oral: 2-4 hours. |
| Duration of Action | IV/IM: 12-36 hours (single dose); oral: 12-36 hours; duration depends on dose, disease severity, and HPA axis suppression. |
| Molecular Weight | 496.53 |
Initial 4-48 mg/day oral in divided doses, tapered. For pulse therapy: 1 g IV daily for 3 days.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment required; use caution in severe renal impairment. |
| Liver impairment | No specific guidelines; caution in severe hepatic impairment. |
| Pediatric use | 0.5-1.7 mg/kg/day or 5-25 mg/m²/day in divided doses. |
| Geriatric use | Lower initial doses recommended due to increased risk of osteoporosis, fluid retention, and immunosuppression. |
| 1st trimester | Risk of cleft palate, intrauterine growth restriction; use only if clearly needed. |
| 2nd trimester | Risk of fetal adrenal suppression; monitor growth. |
| 3rd trimester | Risk of neonatal adrenal suppression; avoid prolonged use. |
Clinical note
Use during pregnancy only if the potential benefit justifies the risk to the fetus. Corticosteroids are associated with increased risk of orofacial clefts and intrauterine growth restriction.
| Placental transfer | Crosses placenta; metabolized by placental 11β-HSD2 to less active form, but significant transfer occurs. |
| Breastfeeding | Corticosteroids enter breast milk in low concentrations; with high maternal doses, monitor infant for adrenal suppression. |
| Lactation Rating |
■ FDA Black Box Warning
Corticosteroids, including methylprednisolone, may cause immunosuppression and increase susceptibility to infections. Live or live attenuated vaccines are contraindicated in patients receiving immunosuppressive doses. Administration of live vaccines may cause disseminated infection.
| Common Effects | Weight gain, Insomnia, Increased appetite, Mood swings, Fluid retention, Hypertension, Hyperglycemia, Osteoporosis |
| Serious Effects | Adrenal crisis, Cushing's syndrome, Severe infections, Avascular necrosis of femoral head, Myocardial rupture post-MI |
Systemic fungal infectionKnown hypersensitivity to methylprednisolone or any component
| Precautions | Increased risk of infections; monitor for signs of infection and avoid exposure to active infections., Adrenal suppression may occur, especially with prolonged therapy; taper dosing gradually., May cause fluid and electrolyte disturbances (e.g., sodium retention, potassium loss, hypertension)., Gastrointestinal perforation risk, especially in patients with inflammatory bowel disease or recent GI surgery., Osteoporosis with long-term use., Behavioral and mood disturbances (e.g., euphoria, depression, psychosis)., Cushing's syndrome with chronic use., Exacerbation of diabetes mellitus, glaucoma, and cataracts., High-dose therapy may cause acute myopathy, particularly in patients on neuromuscular blocking agents. |
Loading safety data…
| L2 (Probably Compatible) |
| Teratogenic Risk | First trimester: Corticosteroids are associated with a small increased risk of oral clefts (odds ratio ~1.5). Second and third trimesters: Chronic use may lead to fetal adrenal suppression, intrauterine growth restriction, and preterm birth. Risk is dose- and duration-dependent. |
| Fetal Monitoring | Maternal: blood pressure, blood glucose, signs of infection, adrenal suppression. Fetal: serial growth ultrasound, assessment for intrauterine growth restriction, adrenal function in neonates if prolonged use. |
| Fertility Effects | Corticosteroids may affect fertility by disrupting menstrual cycles and ovulation, but no specific effects on fertility have been reported for this drug. Chronic use may suppress ovulation. Reversible upon discontinuation. |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they may increase methylprednisolone levels. Limit sodium intake to reduce fluid retention. Avoid alcohol due to increased risk of gastrointestinal bleeding. Maintain adequate calcium and vitamin D intake to prevent bone loss. |
| Clinical Pearls | A-Methapred is a brand of methylprednisolone sodium succinate. For acute spinal cord injury, administer within 8 hours with a bolus of 30 mg/kg over 15 minutes, followed by a 45-minute pause, then 5.4 mg/kg/hour for 23 hours. Monitor for hyperglycemia, especially in diabetic patients; consider insulin sliding scale. Taper dose if used for >5 days to avoid adrenal insufficiency. Avoid abrupt discontinuation. |
| Patient Advice | Do not stop taking this medication suddenly without consulting your doctor; dosage must be tapered gradually. · Report any signs of infection (fever, sore throat, cough) or unusual bleeding/bruising immediately. · Avoid live vaccines while on this medication. · Take with food or milk to reduce stomach upset. · Carry a medical alert card stating you are taking corticosteroids. · Do not miss doses; take exactly as prescribed. |